NSABP P-1 TRIAL

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。乳腺癌是影响美国女性的最常见的恶性肿瘤，也是癌症死亡的第二大原因。我们参与了几个国家外科辅助乳房项目(NSABP)的研究。这些多机构研究考察了乳腺癌的预防(三苯氧胺P-1试验)和治疗。这项预防研究的早期结果表明，在接受他莫昔芬治疗的患者组中，乳腺癌的发病率降低了45%。研究结果已经公布，但尚未公布。所有参与者都得到了通知，目前仍在跟踪调查。NSABP还没有决定这些患者将被随访多少年。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Breast cancer is the most common malignancy affecting women in the US, and the second leading cause of cancer death. We have participated in several National Surgical Adjuvant Breast Project (NSABP) studies. These multi-institutional investigations have examined both prevention (Tamoxifen P-1 Trial) and treatment of breast cancer. The early results of this prevention study demonstrated a decrease in the incidence of breast cancer of 45% in the group of patients who received tamoxifen. The study results were reported, but not yet published. All participants were informed and are still being followed. The NSABP has not decided how many years these patients will be followed.